Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

P_etheris May. 13 at 1:43 PM

$GNPX Another pump on ASGCT for dilution?😅 I wouldn’t be surprised 🤷🏻‍♂️

0 · Reply

Abo_Hamza May. 13 at 11:49 AM

$GNPX should we see any data today about today meeting for diabetics

1 · Reply

StockCaptain7 May. 13 at 12:16 AM

$GNPX Look at that after hours close. Somebody is loading up right at the buzzer before the presentation later today. The comeback is definitely on. Nfa

0 · Reply

StockCaptain7 May. 12 at 11:16 PM

$GNPX The 89th minute comeback. Being a Genprex investor right now feels exactly like being 5-0 down in the 89th minute of a cup final. Rain pouring. Fans leaving the stadium. Manager looks finished. 😂 We are all exhausted, battered, and questioning every life decision. But today is Wednesday May 13th, and we finally get the GPX-002 diabetes data at ASGCT. I’m not saying it moves. I’m not saying miracles happen. But this is one of the few real things we’ve had to watch in a while. I’m still holding the line. Who’s standing with me? Drop your wildest predictions below 👀 NFA #ASGCT2026 #GeneTherapy #Diabetes #Biotech

2 · Reply

StockCaptain7 May. 12 at 11:13 PM

$GNPX hasn’t sold any genprex yet

1 · Reply

OverTheCounter May. 12 at 10:54 PM

$GNPX Another incoming R/S? What happened the Congress man gave up?

0 · Reply

StockCaptain7 May. 12 at 9:27 PM

$GNPX $5 soon bro! That’s what we need 😉

0 · Reply

Jsubsierra May. 12 at 9:03 PM

$GNPX cualquier dia abrira con un +1000 pero yo no estaré dentro. Suerte a todos

0 · Reply

P_etheris May. 12 at 3:13 PM

$GNPX 🤣🤣🤣 NEXT Level —-> 0.7-0.75 THIS WEEK🚨

0 · Reply

Jpeel1972 May. 12 at 2:06 PM

$GNPX vote no on RS. No company should be allowed to reverse split this many times. It should trigger a warning with Nasdaq

2 · Reply

Genprex receives patent grant from The Israel Patent Office

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Apr 28, 2026, 7:00 AM EDT - 15 days ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

2026-04-21T11:09:56.000Z - 22 days ago

Genprex enters research agreement with UT MD Anderson

Apr 21, 2026, 7:00 AM EDT - 22 days ago

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

2026-04-20T11:26:41.000Z - 23 days ago

Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR

Apr 20, 2026, 7:00 AM EDT - 23 days ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

2026-03-18T11:11:22.000Z - 2 months ago

Genprex collaborators present on use of Reqorsa at AACR meeting

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Genprex to Participate at BIO Europe Spring 2026

2026-02-23T13:12:47.000Z - 2 months ago

Genprex granted Japanese and EU patents for Reqorsa Gene Therapy

Feb 23, 2026, 8:00 AM EST - 2 months ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

2026-02-10T13:05:58.000Z - 3 months ago

Genprex’s patent application for Reqorsa Gene Therapy accepted by IP Australia

Feb 10, 2026, 8:00 AM EST - 3 months ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Jan 7, 2026, 7:00 AM EST - 4 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

2026-01-06T12:05:20.000Z - 4 months ago

Genprex reports ‘positive’ preclinical data from study of GPX-002

Jan 6, 2026, 7:00 AM EST - 4 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

2025-11-24T12:10:18.000Z - 6 months ago

Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

Nov 24, 2025, 7:00 AM EST - 6 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

2025-11-21T22:00:33.000Z - 6 months ago

Genprex files to sell 1.28M shares of common stock for holders

2025-11-19T12:10:46.000Z - 6 months ago

Genprex adds Gabrail Cancer Center for Acclaim clinical trials 1 and 3

AZN

Nov 19, 2025, 7:00 AM EST - 6 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

2025-11-18T12:21:46.000Z - 6 months ago

Genprex granted U.S. patenet for Reqorsa Gene Therapy in cancer

Nov 18, 2025, 7:00 AM EST - 6 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

2025-11-04T12:50:41.000Z - 6 months ago

Genprex on path to receive European patent for Reqorsa in cancer

Nov 4, 2025, 7:00 AM EST - 6 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

2025-10-28T15:30:20.000Z - 7 months ago

Genprex trading resumes

2025-10-28T15:25:18.000Z - 7 months ago

Genprex trading halted, volatility trading pause

2025-10-28T15:25:12.000Z - 7 months ago

Genprex announces registered direct offering of up to $10M

Oct 28, 2025, 11:19 AM EDT - 7 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

2025-10-28T11:11:48.000Z - 7 months ago

Genprex presents positive preclinical data on Reqorsa Gene Therapy

Oct 28, 2025, 7:00 AM EDT - 7 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-23T12:15:23.000Z - 7 months ago

Genprex announces $8.1M registered direct offering priced at-the-market

Oct 23, 2025, 8:12 AM EDT - 7 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 7 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-20T23:50:17.000Z - 7 months ago

Genprex trading halted, news pending

2025-09-12T20:50:09.000Z - 8 months ago

Genprex files to sell 25M shares of common stock for holders

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 9 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 11 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 11 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 1 year ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 1 year ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

P_etheris May. 13 at 1:43 PM

$GNPX Another pump on ASGCT for dilution?😅 I wouldn’t be surprised 🤷🏻‍♂️

0 · Reply

Abo_Hamza May. 13 at 11:49 AM

$GNPX should we see any data today about today meeting for diabetics

1 · Reply

StockCaptain7 May. 13 at 12:16 AM

$GNPX Look at that after hours close. Somebody is loading up right at the buzzer before the presentation later today. The comeback is definitely on. Nfa

0 · Reply

StockCaptain7 May. 12 at 11:16 PM

2 · Reply

StockCaptain7 May. 12 at 11:13 PM

$GNPX hasn’t sold any genprex yet

1 · Reply

OverTheCounter May. 12 at 10:54 PM

$GNPX Another incoming R/S? What happened the Congress man gave up?

0 · Reply

StockCaptain7 May. 12 at 9:27 PM

$GNPX $5 soon bro! That’s what we need 😉

0 · Reply

Jsubsierra May. 12 at 9:03 PM

$GNPX cualquier dia abrira con un +1000 pero yo no estaré dentro. Suerte a todos

0 · Reply

P_etheris May. 12 at 3:13 PM

$GNPX 🤣🤣🤣 NEXT Level —-> 0.7-0.75 THIS WEEK🚨

0 · Reply

Jpeel1972 May. 12 at 2:06 PM

$GNPX vote no on RS. No company should be allowed to reverse split this many times. It should trigger a warning with Nasdaq

2 · Reply

OfficialStocktwitsUser May. 12 at 12:09 PM

$GNPX RSI: 26.31, MACD: -0.1789 Vol: 0.15, MA20: 1.02, MA50: 1.48 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Fisherofmen May. 12 at 11:11 AM

$GNPX

0 · Reply

zannnn May. 12 at 9:34 AM

$GNPX

0 · Reply

StockCaptain7 May. 12 at 8:27 AM

$GNPX I posted about ASGCT yesterday, so no point repeating the same thing. The real thing I’m watching now is what comes after the GPX-002 poster. Do they give more detail on tox studies? Manufacturing? IND path? The market clearly doesn’t care about another conference headline on its own. At this point holders need execution, not just awareness. Still watching, but I want to see something concrete.

0 · Reply

Tpritch007 May. 12 at 1:04 AM

$GNPX I’ve played this stock multiple times over the years when it was beat down, and made good money more times than not. Very disappointing, this go round has been even more of a kick in the nuts than the normal playbook.

1 · Reply

StockCaptain7 May. 11 at 9:31 PM

$GNPX Biotech Stock Catalyst Watchlist

0 · Reply

ProfessorDman1 May. 11 at 6:34 PM

$GNPX took few .80s (swing )

0 · Reply

StockCaptain7 May. 11 at 4:01 PM

$GNPX Everyone’s tired here, I get it. ASGCT week is here. GPX-002 Type 2 diabetes preclinical data being presented in Boston, May 11–15. Not calling miracles, but the diabetes side is still moving. Let’s see if the market cares this time.

0 · Reply

zannnn May. 11 at 12:22 PM

$GNPX

0 · Reply

P_etheris May. 11 at 10:28 AM

$GNPX It took so long, but below 80c is coming today☝️

0 · Reply

jogee123 May. 10 at 11:02 AM

$GNPX CEO of GNP

0 · Reply

P_etheris May. 9 at 7:11 AM

$GNPX Agreed☝️ I don’t understand“ the master plan “ of Confer… keep diluting for pennies… He is an absolute Kant… imperative!

0 · Reply

Market Cap	8.81M
Revenue (ttm)	0.00
Net Income (ttm)	-16.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	192,400
Avg Vol	739,528
Day's Range	N/A - N/A
Shares Out	10.42M
Stochastic %K	9%
Beta	-0.94
Analysts	Strong Buy
Price Target	$7.50